Prelude Therapeutics (PRLD) Competitors $0.81 +0.04 (+5.19%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.81 0.00 (-0.37%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. ACIU, TARA, DMAC, IKT, PBYI, TNGX, DERM, OGI, LYEL, and SCPHShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include AC Immune (ACIU), Protara Therapeutics (TARA), DiaMedica Therapeutics (DMAC), Inhibikase Therapeutics (IKT), Puma Biotechnology (PBYI), Tango Therapeutics (TNGX), Journey Medical (DERM), Organigram (OGI), Lyell Immunopharma (LYEL), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. AC Immune Protara Therapeutics DiaMedica Therapeutics Inhibikase Therapeutics Puma Biotechnology Tango Therapeutics Journey Medical Organigram Lyell Immunopharma scPharmaceuticals Prelude Therapeutics (NASDAQ:PRLD) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking. Does the MarketBeat Community favor PRLD or ACIU? AC Immune received 229 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 62.65% of users gave AC Immune an outperform vote while only 50.00% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes3150.00% Underperform Votes3150.00% AC ImmuneOutperform Votes26062.65% Underperform Votes15537.35% Do insiders and institutionals hold more shares of PRLD or ACIU? 79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PRLD or ACIU more profitable? AC Immune's return on equity of -28.26% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% AC Immune N/A -28.26%-18.98% Do analysts rate PRLD or ACIU? Prelude Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 393.83%. AC Immune has a consensus price target of $12.00, suggesting a potential upside of 710.81%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33AC Immune 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, PRLD or ACIU? Prelude Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Does the media favor PRLD or ACIU? In the previous week, AC Immune had 9 more articles in the media than Prelude Therapeutics. MarketBeat recorded 9 mentions for AC Immune and 0 mentions for Prelude Therapeutics. AC Immune's average media sentiment score of 1.57 beat Prelude Therapeutics' score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Overall Sentiment Prelude Therapeutics Neutral AC Immune Very Positive Which has higher earnings & valuation, PRLD or ACIU? AC Immune has higher revenue and earnings than Prelude Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M6.53-$121.83M-$1.69-0.48AC Immune$27.31M5.44-$60.41M-$0.58-2.55 SummaryAC Immune beats Prelude Therapeutics on 12 of the 16 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.73M$6.45B$5.31B$7.34BDividend YieldN/A3.21%5.45%4.34%P/E Ratio-0.466.9221.9417.82Price / Sales6.53231.01380.6697.73Price / CashN/A65.6738.2534.64Price / Book0.195.936.453.98Net Income-$121.83M$143.22M$3.22B$247.81M7 Day Performance16.71%1.15%0.74%0.28%1 Month Performance13.99%-13.22%-9.66%-7.60%1 Year Performance-78.23%-8.51%11.81%1.49% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics1.8126 of 5 stars$0.81+5.2%$4.00+393.8%-78.2%$45.73M$7M-0.46120Gap UpACIUAC Immune2.5072 of 5 stars$1.52-2.6%$12.00+689.5%-37.3%$152.62M$27.31M-3.30140Positive NewsTARAProtara Therapeutics1.9184 of 5 stars$4.14+5.9%$22.50+443.5%+47.7%$152.22MN/A-1.4730Positive NewsGap UpDMACDiaMedica Therapeutics1.3536 of 5 stars$3.54+2.0%$8.00+126.0%+48.1%$151.71MN/A-6.3220Short Interest ↑News CoverageGap UpIKTInhibikase Therapeutics1.0348 of 5 stars$2.00-3.4%$6.50+225.0%-7.1%$148.68M$260,000.00-0.756PBYIPuma Biotechnology3.528 of 5 stars$2.93+3.9%$7.00+138.9%-42.9%$145.36M$230.47M6.10200TNGXTango Therapeutics1.9159 of 5 stars$1.34-5.0%$12.33+820.4%-82.4%$144.87M$42.07M-1.1490Gap UpDERMJourney Medical2.408 of 5 stars$6.21+3.0%$9.88+59.0%+79.6%$143.48M$56.13M-6.6190Short Interest ↑Positive NewsOGIOrganigram0.6457 of 5 stars$1.04+1.0%N/A-43.4%$131.31M$166.12M-2.74860Positive NewsLYELLyell Immunopharma3.1971 of 5 stars$0.44+1.4%$1.00+124.9%-80.6%$131.26M$61,000.00-0.56270Gap DownSCPHscPharmaceuticals3.7824 of 5 stars$2.58+11.2%$14.00+442.6%-43.6%$129.73M$36.33M-1.3630Short Interest ↓Gap Up Related Companies and Tools Related Companies AC Immune Alternatives Protara Therapeutics Alternatives DiaMedica Therapeutics Alternatives Inhibikase Therapeutics Alternatives Puma Biotechnology Alternatives Tango Therapeutics Alternatives Journey Medical Alternatives Organigram Alternatives Lyell Immunopharma Alternatives scPharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRLD Stock Free PRLD Stock Alerts